Clinical trial NCT06993662: The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective.
Official title: The Effectiveness and Efficacy of the Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective for Patients With Mental Health Disorders
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Anxiety
Depression
Obsessive-compulsive Disorder
Personality Disorder
Bipolar Disorder
Schizophrenia
Psychotic Disorders
PTSD
Keywords: Pharmacotherapy
Cognitive behavioral psychotherapy
Recovery
Lead sponsor: Rakitzi, Stavroula
Sponsor class: OTHER
First posted: 2025-05-29
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The combination of pharmacotherapy and individual cognitive behavioral therapy in a private practice.

Detailed description: Reintegration into society and good functional outcome by people with mental health disorders is frequently the result of the combination of pharmacotherapy and individual cognitive behavioral psychotherapy. The effectiveness and efficacy of this combination of treatments under the recovery perspective by anxiety disorders, depressive disorders, PTSD, bipolar disorders, schizophrenia and psychotic disorders, by obsessive-compulsive disorders and by personality disorders presents the main goal of this research protocol. Recovery means that people learn through the trherapy to be responsible towards their own problems.

Eligibility criteria: Inclusion Criteria:

* age 18-65,
* IQ ≥ 80,
* Diagnosis: anxiety disorders, depression, obsessive-compulsive disorders, PTSD, personality disorders, bipolar disorders, schizophrenia and psychotic disorders.

Exclusion Criteria:

\*Substance abuse and head injury.

Primary outcomes:
measure: MCCB BACS symbol coding
timeFrame: Preintervention
measure: MCCB BACS symbol coding
timeFrame: Immediately after the intervention
measure: MCCB BACS symbol coding
timeFrame: Follow-up up to 24 weeks
measure: MCCB Wechsler memory scale-spatial span
timeFrame: Preintervention
measure: MCCB Wechsler memory scale-spatial span
timeFrame: Immediately after the intervention
measure: MCCB Wechsler memory scale-spatial span
timeFrame: Follow-up up to 24 weeks
measure: MCCB Neurospychological Assessment Battery (NAB)
timeFrame: Preintervention
measure: MCCB Neurospychological Assessment Battery (NAB)
timeFrame: Immediately after the intervention
measure: MCCB Neurospychological Assessment Battery (NAB)
timeFrame: Follow-up up to 24 weeks
measure: MCCB Brief visuospatial memory test
timeFrame: Preintervention
measure: MCCB Brief visuospatial memory test
timeFrame: Immediately after the intervention
measure: MCCB Brief visuospatial memory test
timeFrame: Follow-up up to 24 weeks
measure: The Greek verbal memory test
timeFrame: Preintervention
measure: The Greek verbal memory test
timeFrame: Immediately after the intervention
measure: The Greek verbal memory test
timeFrame: Follow-up up to 24 weeks
measure: The Greek verbal memory test
timeFrame: Preintervention
measure: The Greek verbal memory test
timeFrame: Immediately after the intervention
measure: The Greek verbal memory test
timeFrame: Follow-up up to 24 weeks
measure: The Greek verbal memory test
timeFrame: Preintervention
measure: The Greek verbal memory test
timeFrame: Immediately after the intervention
measure: The Greek verbal memory test
timeFrame: Follow-up up to 24 weeks
measure: The Greek verbal memory test
timeFrame: Preintervention
measure: The Greek verbal memory test
timeFrame: Immediately after the intervention
measure: The Greek verbal memory test
timeFrame: Follow-up up to 24 weeks
measure: SCL-90-R
timeFrame: Preintervention
measure: SCL-90-R
timeFrame: Immediately after the intervention
measure: SCL-90-R
timeFrame: Follow-up up to 24 weeks
measure: PANNS total
timeFrame: Preintervention
measure: PANNS total
timeFrame: Immediately after the intervention
measure: PANNS total
timeFrame: Follow-up up to 24 weeks
measure: WHODAS total
timeFrame: Preintervention
measure: WHODAS total
timeFrame: Immediately after the intervention
measure: WHODAS total
timeFrame: Follow-up up to 24 weeks
measure: RAS-DS total
timeFrame: Preintervention
measure: RAS-DS total
timeFrame: Immediately after the intervention
measure: RAS-DS total
timeFrame: Follow-up up to 24 weeks
measure: The Clinical Global Impression Scale (CGI)
timeFrame: Preintervention
measure: The Clinical Global Impression Scale (CGI)
timeFrame: Immediately after the intervention
measure: The Clinical Global Impression Scale (CGI)
timeFrame: Follow-up up to 24 weeks
measure: The Clinical Global Impression Scale (CGI)
timeFrame: Preintervention
measure: The Clinical Global Impression Scale (CGI)
timeFrame: Immediately after the intervention
measure: The Clinical Global Impression Scale (CGI)
timeFrame: Follow-up up to 24 weeks
measure: SRSDA
timeFrame: Preintervention
measure: SRSDA
timeFrame: Immediately after the intervention
measure: SRSDA
timeFrame: Follow-up up to 24 weeks
measure: SRSDA B
timeFrame: Preintervention
measure: SRSDA B
timeFrame: Immediately after the intervention
measure: SRSDA B
timeFrame: Follow-up up to 24 weeks
measure: Hamilton Depression Scale
timeFrame: Preintervention
measure: Hamilton Depression Scale
timeFrame: Immediately after the intervention
measure: Hamilton Depression Scale
timeFrame: Follow-up up to 24 weeks
measure: Montgomery and Asperg depression scale
timeFrame: Preintervention
measure: Montgomery and Asperg depression scale
timeFrame: Immediately after the intervention
measure: Montgomery and Asperg depression scale
timeFrame: Follow-up up to 24 weeks
measure: The Altman self-rating scale
timeFrame: Preintervention
measure: The Altman self-rating scale
timeFrame: Immediately after the intervention
measure: The Altman self-rating scale
timeFrame: Follow-up up to 24 weeks
measure: The Young mania rating scale
timeFrame: Preintervention
measure: The Young mania rating scale
timeFrame: Immediately after the intervention
measure: The Young mania rating scale
timeFrame: Follow-up up to 24 weeks
measure: PSYRAT H
timeFrame: Preintervention
measure: PSYRAT H
timeFrame: Immediately after the intervention
measure: PSYRAT H
timeFrame: Follow-up up to 24 weeks
measure: PSYRAT D
timeFrame: Preintervention
measure: PSYRAT D
timeFrame: Immediately after the intervention
measure: PSYRAT D
timeFrame: Follow-up up to 24 weeks
Secondary outcomes:
measure: WAIS
timeFrame: Preintervention
Other outcomes:
Locations:
city: Athens
country: Greece
facility: Private practice of Dr. S. Rakitzi and Dr. P. Georgila ILISION 34 15771 ATHENS GREECE
Study officials:
affiliation: Private Practice
name: Dr. Stavroula Rakitzi, PhD
role: STUDY_DIRECTOR
affiliation: Private Practice
name: Dr. Polyxeni Georgila, M. D.
role: STUDY_DIRECTOR
References:
citation: 2. Aster, M., Neubauer, M., & Horn R. (2006) Wechsler-Intelligenztest für Erwachsene WIE. Frankfurt: Harcourt Test Services.
citation: Altman EG, Hedeker D, Peterson JL, Davis JM. The Altman Self-Rating Mania Scale. Biol Psychiatry. 1997 Nov 15;42(10):948-55. doi: 10.1016/S0006-3223(96)00548-3.
citation: Bech, P. (1993). Rating scales for Psychopathology, Health Status and Quality of Life. Berlin, Heidelberg, New York: Springer-Verlag.
citation: Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007 Jul;4(7):28-37.
citation: Donias, S., Karastergiou, A., & Manos N. (1991). Standardization of the symptom checklist-90-R rating scale in a Greek population. Psychiatriki, 2(1), 42-48
citation: Fountoulakis KN, Iacovides A, Kleanthous S, Samolis S, Gougoulias K, St Kaprinis G, Bech P. The Greek translation of the symptoms rating scale for depression and anxiety: preliminary results of the validation study. BMC Psychiatry. 2003 Dec 10;3:21. doi: 10.1186/1471-244X-3-21.
citation: Guy, W. (ed). (1976). ECDEU Assessment. Manual for Psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, 1976
citation: Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychol Med. 1999 Jul;29(4):879-89. doi: 10.1017/s0033291799008661.
citation: Hancock, N., Scanlan, J.N., Bundy, A.C., Honey, A. (2019). Recovery Assessment Scale -Domains & Stages (RAS-DS) Manual- Version 3. Sydney: University of Sydney.
citation: Hancock, N., & the University of Sydney (2023). Rakitzi S. Katoudi S. Recovery Assessment Scale-Domains & Stages (RAS-DS). The Greek version.
citation: Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261.
citation: .Kosmidou, M., & Vlahou, Ch. (2010). The Greek verbal memory test. Athens: Parisianos.
citation: Koumpouros, Y., Papageorgiou, E., & Sakellari E. et al. (2018). Adaptation and psychometric properties evaluation of the Greek version of WHODAS 2.0. Pilot application in Greek elderly population. Health Services and Outcomes Research Methodology, 18(1), 63-74. https://doi.org/10.1007/s10742-017- 0176-x
citation: .Lykouras, L., Botsis, A., & Oulis P. (2005). The PANSS Scale. Athens: Scientific Publications
citation: Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9. doi: 10.1192/bjp.134.4.382.
citation: Rakitzi, S. (2023). Clinical psychology and cognitive behavioral psychotherapy. Recovery in mental health. Springer
citation: Williams JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008 Jan;192(1):52-8. doi: 10.1192/bjp.bp.106.032532.
citation: World Health Organization. International classification of functioning, disability and health (ICF). Geneva: World Health Organization; 2001
citation: Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978 Nov;133:429-35. doi: 10.1192/bjp.133.5.429.